New findings in fetal valproate syndrome: Hiatal hernia, gastric volvulus and ectopic kidney
Yükleniyor...
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Taylor & Francis Inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
It is known that use of several antiepileptic drugs (AED) during pregnancy has been associated with an increased risk of major congenital anomalies. Approximately one in 250 pregnancies is known to be exposed to AED and a significant proportion of these are exposed to valproate, either as monotherapy or as part of a polytherapy drug regimen (Lindhout and Omtzigt 1992). Valproic acid (VPA) also has relatively less sedative and behavioural effects. Because of the previous reports suggesting a decreased risk of adverse pregnancy outcome, VPA was used extensively. It is a popular drug used for the treatment of seizures because of its broad range of anticonvulsant effect. It is generally accepted that the lowest dose at which the patient is seizure free should be used during pregnancy. The dose of VPA is titrated according to the clinical response (ClaytonSmith and Donnai 1995) Several studies have also shown that
VPA doses over 1000 mg/day are associated with a doubling of the risk for the fetus (Morrow et al. 2006) Fetal valproate syndrome (FVS) is seen in infants after in utero exposure to sodium valproate, with typical facial appearance, various malformations and neurodevelopmental delay. It can be characterised by neural tube defects, congenital heart disease, genitourinary, skeletal and respiratory system anomalies, brain, eye and abdominal wall defects (Ozkan et al. 2011)
Açıklama
Anahtar Kelimeler
Fetal Valproate Syndrome, Hiatal Hernia, Gastric Volvulus, Ectopic Kidney
Kaynak
Journal Of Obstetrics And Gynaecology
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
36
Sayı
6
